Mani Foroohar of SVB Leerink, Reiterated "BridgeBio Pharma, Inc." (BBIO) at Buy with Decreased Target from $41 to $39 on, May 14th, 2020.
Mani has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Mani
- Raghuram Selvaraju of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $50 on, Monday, April 13th, 2020
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $43 on, Tuesday, March 3rd, 2020
- Salim Syed of "Mizuho" Initiated at Strong Buy and Held Target at $51 on, Wednesday, February 19th, 2020
